Cargando…

P625: A PHASE 1B/2 STUDY OF NAVTEMADLIN COMBINED WITH ACALABRUTINIB IN BTK INHIBITOR NAÏVE PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Detalles Bibliográficos
Autores principales:	Byrd, John C., Ali Bhat, Seema, Awan, Farrukh, Giri, Pratyush, Ratnasingam, Sumita, Hájek, Roman, Hess, Dagmar, Alves, Daniela, Maciej Zaucha, Jan, Shen, Annalise, Bilotti, Elizabeth, Mcgreivy, Jesse, P. Rothbaum, Wayne, Ciepluch, Hanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428975/ http://dx.doi.org/10.1097/01.HS9.0000969404.19790.4a

Ejemplares similares

Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance
por: St-Pierre, Frédérique, et al.
Publicado: (2022)

The spectrum of coincident entities with small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) diagnosed by cytology
por: Kastenbaum, Hannah A., et al.
Publicado: (2010)

Bilateral breast implant associated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A case report
por: Bletsis, Patrick P., et al.
Publicado: (2020)

P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)
por: Eichhorst, Barbara, et al.
Publicado: (2023)

S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)
por: Vachhani, Pankit, et al.
Publicado: (2023)

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
por: Zhu, Sining, et al.
Publicado: (2021)

MUM1/IRF4 Expression Is an Unfavorable Prognostic Factor in B‐Cell Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
por: Ito, Masato, et al.
Publicado: (2002)

P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY
por: Munir, Talha, et al.
Publicado: (2023)

Folliculocentric lymphocytic hypersensitivity reactions in CLL/SLL patients: A unique clinicopathologic entity amongst non‐specific hypersensitivity reactions
por: Abbott, James, et al.
Publicado: (2023)

The role of acalabrutinib in adults with chronic lymphocytic leukemia
por: Fakhri, Bita, et al.
Publicado: (2021)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

Sclerosing lymphocytic lobulitis (SLL): a diagnostic challenge
por: Dutta, S, et al.
Publicado: (2000)

Clinical course of COVID-19 in a patient with refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) under ibrutinib therapy: a case report
por: Cecyn, Karin Zattar, et al.
Publicado: (2021)

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
por: Wu, Jingjing, et al.
Publicado: (2016)

Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib
por: Lin, David Y., et al.
Publicado: (2023)

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma
por: Harrington, Bonnie K., et al.
Publicado: (2016)

Acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukaemia
Publicado: (2020)

Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective
por: Sood, Nitin, et al.
Publicado: (2021)

Acalabrutinib in Membranous Nephropathy Associated With Chronic Lymphocytic Leukemia
por: Izzedine, Hassan, et al.
Publicado: (2022)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

Case report: rare case of infiltration of small lymphocytic B-cell lymphoma in the thyroid gland of female patient with B-cell chronic lymphocytic leukemia (CLL-B/SLL-B)
por: Andrysiak-Mamos, Elżbieta, et al.
Publicado: (2013)

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
por: Nicolson, Phillip L.R., et al.
Publicado: (2018)

Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib
por: Vitale, Candida, et al.
Publicado: (2021)

PB1911: CYTOGENOMIC INTEGRATIVE ANALYSIS OF CLL/SLL PATIENTS AT DISEASE PROGRESSION.
por: García-Serra, Rocío, et al.
Publicado: (2023)

Real-world prognostic testing and treatment patterns in CLL/SLL: results from 1462 patients in the informCLL registry
por: Mato, Anthony R., et al.
Publicado: (2022)

P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL
por: Simon, Florian, et al.
Publicado: (2023)

Racial and socioeconomic disparities in CLL/SLL: analysis of SEER data from 2006 to 2019
por: Kittai, Adam S., et al.
Publicado: (2022)

Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies
por: Zhu, Sining, et al.
Publicado: (2021)

P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
por: Clevenger, Tracy, et al.
Publicado: (2023)

The Mysterious Actor—γδ T Lymphocytes in Chronic Lymphocytic Leukaemia (CLL)
por: Zarobkiewicz, Michał K., et al.
Publicado: (2022)

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
por: Byrd, John C., et al.
Publicado: (2021)

Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL
por: Forcello, Nicholas, et al.
Publicado: (2014)

Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis
por: Vassilopoulos, Stephanos, et al.
Publicado: (2022)

Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance
por: Omi, Ai, et al.
Publicado: (2022)

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
por: Freeman, Ciara L., et al.
Publicado: (2016)

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023)

Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors
por: Bond, David A, et al.
Publicado: (2020)

Acalabrutinib‐related second primary malignancies and nonmelanoma skin cancers in patients with chronic lymphocytic leukaemia (CLL): A systematic review and meta‐analysis of randomised controlled trials (RCTs)
por: Htut, Thura W., et al.
Publicado: (2020)

P617: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4-Y FOLLOW-UP FROM FD COHORT OF PHASE 2 CAPTIVATE STUDY
por: Ghia, Paolo, et al.
Publicado: (2023)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cgqtbo5koaud2j9ktdt852j367